PERL Continuous Glucose Monitoring (CGM) Study

CompletedOBSERVATIONAL
Enrollment

175

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

August 31, 2019

Study Completion Date

December 31, 2021

Conditions
Diabetic Nephropathies
Interventions
OTHER

Mean blood glucose

Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

Blood glucose CV

Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

% time 70-180 mg/dL

Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

% time below 54 mg/dL

Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

% time above 180 mg/dL

Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

% time above 250 mg/dL

Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

MAGE (Mean amplitude of glucose excursions)

Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

LBGI (Low Blood Glucose Index)

Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

OTHER

HBGI (High Blood Glucose Index)

High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.

DRUG

Allopurinol

Oral allopurinol tablets administered in the PERL Clinical Trial

DRUG

Placebo

Oral placebo tablets administered in the PERL Clinical Trial

Trial Locations (19)

10029

ICAHN School of Medicine at Mount Sinai, New York

10461

Albert Einstein College of Medicine / Montefiore Medical Center, The Bronx

13210

SUNY Upstate Medical University, Syracuse

30303

Emory University - Grady Memorial Hospital, Atlanta

48105

Brehm Center for Diabetes Research / University of Michigan, Ann Arbor

48202

Henry Ford Health System, Detroit

55455

University of Minnesota, Minneapolis

60611

Northwestern University Feinberg School of Medicine, Chicago

63110

Washington University, St Louis

75390

UT Southwestern Dallas, Dallas

80045

Barbara Davis Center / University of Colorado Denver, Aurora

98101

Virginia Mason Medical Center, Seattle

98105

University of Washington, Seattle

99204

Providence Sacred Heart Medical Center, Spokane

02215

Joslin Diabetes Center, Boston

T2T 5C7

Unversity of Calgary, Calgary

T6G2E1

University of Alberta, Edmonton

V5Y 3W2

BC Diabetes, Vancouver

M5T-3L9

University of Toronto, Toronto

All Listed Sponsors
collaborator

The Leona M. and Harry B. Helmsley Charitable Trust

OTHER

collaborator

University of Minnesota

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

University of Michigan

OTHER

collaborator

Northwestern University Feinberg School of Medicine

OTHER

collaborator

Albert Einstein College of Medicine

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

University of Washington

OTHER

collaborator

Providence Medical Research Center

OTHER

lead

Joslin Diabetes Center

OTHER

NCT03334318 - PERL Continuous Glucose Monitoring (CGM) Study | Biotech Hunter | Biotech Hunter